论文部分内容阅读
多重抗药性恶性疟的严重性及分布范围的迅速扩散,给恶性疟的防治带来了极其严峻的问题,寻找新类型的抗疟药实在刻不容缓。酮替芬(Ketotifen)为5—羟色胺(5—HT)类药,常用于抗过敏性疾病。1986年潘星清等发现其对红内期疟原虫有一定的杀灭作用,且能治愈高度抗氯喹株伯氏疟原虫感染,后经临床试用酮替芬合并少量磺胺多辛治疗现症恶性疟和间日疟确有疗效。新近研究表明,酮替芬或同类的赛庚啶(cyproheptadine)单用治疗抗氯喹株伯氏疟原虫较敏感株疗效更佳,与氯喹并用可逆转伯氏疟原虫对氯喹的抗性
The rapid spread of the severity and spread of the multi-resistant falciparum malaria poses an extremely serious problem for the prevention and control of falciparum malaria. It is imperative to find a new type of antimalarial drug. Ketotifen is a serotonin (5-HT) drug, commonly used in anti-allergic diseases. In 1986, Pan Xingqing found that it had certain killing effect on Plasmodium in the red stage and could cure the infection of Plasmodium berghei highly resistant to chloroquine. After clinical trial, ketotifen combined with a small amount of sulfadoxine to treat the present falciparum malaria and Volatile malaria does have efficacy. Recent studies have shown that ketotifen or its equivalent cyproheptadine alone is more effective than the more sensitive strains of Plasmodium berghei against chloroquine. In combination with chloroquine, chloroquine can reverse the resistance of chloroquine to Plasmodium berghei